CCO Treatment Updates
An Eye on the Future: Planning for Long-term Antiretroviral Success
Factors Associated With Long-term Success With First-line Regimens |
Module 1 of 3 |
|
Program Director: W. David Hardy, MD
|
|
Renslow Sherer, MD, addresses factors that contribute to the attainment of long-term virologic suppression in patients initiating antiretroviral therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe patient and viral factors that may impact long-term success of first-line antiretroviral regimens
- Discuss clinical trials of antiretroviral agents that support long-term efficacy and tolerability of agents
- Explain how short-term and long-term adverse events associated with use of antiretroviral agents may affect use in the long term
- Relate how patient comorbidities may affect choice of antiretroviral agents, with emphasis on long-term use of agents
|
Strategies for Further Enhancing Outcomes in Patients With Virologic Suppression |
Module 2 of 3 |
|
Program Director: W. David Hardy, MD
- Edwin DeJesus, MD, FACP, AAHIVS
|
|
|
Edwin DeJesus, MD, FACP, AAHIVS, outlines strategies for treatment simplification in virologically suppressed patients and discusses data that indicate that this is a safe and effective strategy in many patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount practice guideline recommendations regarding treatment simplification strategies for virologically suppressed patients
- Discuss the results of clinical trials of virologically suppressed patients who switched single agents within the same classes
- Describe the results of clinical trials of virologically suppressed patients who had treatment simplified to coformulated agents
|
Management Challenges in Patients Receiving Long-term Antiretroviral Therapy |
Module 3 of 3 |
|
Program Director: W. David Hardy, MD
|
|
Matthew B. Goetz, MD, reviews management issues in older HIV- infected patients who have undergone long-term therapy with antiretroviral medications and explores the intersection of HIV infection, antiretroviral therapy, and/or the normal aging process.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe how the elderly population of HIV-infected patients has increased in the United States
- Discuss the clinical course of HIV-1 in the elderly
- Explain the role of HIV-1 in clinical complications of aging
- Relate how complications of antiretroviral therapy overlap with comorbidities of aging
- Discuss management issues for this population
|
Video Module
Planning and Strategizing for Long-term Success With Antiretroviral Therapy
|
Program Director: W. David Hardy, MD
 
- Edwin DeJesus, MD, FACP, AAHIVS
- Matthew B. Goetz, MD
- Renslow Sherer, MD
|
|
|
W. David Hardy, MD, leads a case-based roundtable discussion with Renslow Sherer, MD, Edwin DeJesus, MD, FACP, AAHIVS, and Matthew B. Goetz, MD, to determine strategies important for long-term antiretroviral therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe considerations that are important for long-term success of a first-line antiretroviral regimen
- Explain factors that should influence the decision when considering modification of antiretroviral therapy in a virologically suppressed patient
- Discuss how morbidities related to aging may have affect choice of antiretroviral agents in patients who are middle aged and have been on antiretroviral therapy for many years
|
CCO Slideset
An Eye on the Future: Planning for Long-term Antiretroviral Success
 |
|
W. David Hardy, MD, reviews data important in supporting long-term suppression in patients starting therapy, those who are suppressed but might benefit from modifying therapy, and those who have been receiving therapy for many years.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.76 MB
| Date posted: 2/11/2009
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|